A Randomized, Placebo-Controlled, Double-Blind, Phase III/VI study to compare the efficacy and safety of investigational drug  weekly infusion vs. placebo in subjects with emphysema due to alpha-1 proteinase inhibitor deficiency

The purpose of this study is to investigate the effect of investigational drug on the progression of emphysema, assessed by the decline of lung density, measured by CT, and to assess the effect of treatment with alpha-1 proteinase inhibitor on the number, severity and duration of exacerbation. This study will take two years and involves 10 visits. Participants will receive study-related medical care at no cost and reimbursement for your time and travel expenses.

You may be eligible to participate in this study if you:

• Are 18 to 65 years old
• Have serum A1-PI level less than 11mmol/l or 80 mg/ml
• Are not a current tobacco smoker

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.